Letters to the Editor

Bi 38-3 is a novel CD38/CD3 bispecific T-cell engager with low toxicities for the treatment of multiple myeloma.

Institut de recherche Saint-Louis, Inserm U976;
Institut de recherche Saint-Louis, InsermU976;
Institut de recherche Saint-Louis, Inserm U976;
Institut de recherche Saint-Louis, Inserm U976;
Institut de recherche Saint-Louis, Inserm U976;
Institut de recherche Saint-Louis, Inserm U976;
Immunology-Haematology department, Hôpital Saint-Louis, AP-HP
Institut de recherche Saint-Louis, Inserm U976;
Immunology-Haematology department, Hôpital Saint-Louis, AP-HP
Immunology-Haematology department, Hôpital Saint-Louis, AP-HP
Institut de recherche Saint-Louis, Inserm U976;
Haematologica Early view Jul 16, 2020 https://doi.org/10.3324/haematol.2019.242453